| 中文名 | 2-肼基腺苷 |
|---|---|
| 英文名 | 2-Hydrazino Adenosine |
| 中文别名 |
雷加登森杂质22
瑞加德松杂质19 2-肼腺苷 (2R,3R,4S,5R)-2-(6-氨基-2-肼基-9H-嘌呤-9-基)-5-(羟甲基)四氢呋喃-3,4-二醇 瑞加诺生杂质I 肼基腺苷杂质2 瑞加德松杂质22 肼基腺苷杂质2(瑞加德松杂质22) |
| 英文别名 |
(2R,3R,4S,5R)-2-(6-amino-2-hydrazinylpurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
(2R,3R,4S,5R)-2-((Z)-6-amino-2-hydrazono-2H-purin-9(3H)-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol Regadenoson Impurity 22 Adenosine, 2-hydrazinyl (3R, 4S, 5R)-2-(6-amino-2-hydrazinyl-9H-purin-9-yl)-5-(hydroxymethyl) tetrahydrofuran-3,4-diol (2R,3R,4S,5R)-2-(6-amino-2-hydrazinyl-9H-purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol Hydrazinoadenosine impurity 2(Regdsone impurity 22) BINO-006 Regadenoson Impurity 19 |
| 描述 | 2-肼基腺苷是嘌呤核苷类似物。嘌呤核苷类似物具有广泛的抗肿瘤活性,靶向惰性淋巴系统恶性肿瘤。这一过程中的抗癌机制依赖于抑制DNA合成、诱导细胞凋亡等[1]。 |
|---|---|
| 相关类别 | |
| 参考文献 |
| 密度 | 2.29±0.1 g/cm3(Predicted) |
|---|---|
| 沸点 | 583.1±60.0 °C(Predicted) |
| 熔点 | 208-210ºC |
| 分子式 | C10H15N7O4 |
| 分子量 | 297.27 |
| 精确质量 | 297.11900 |
| PSA | 177.59000 |
| 外观性状 | 白色固体 |
| 折射率 | 2.002 |
| 储存条件 | 2-8°C |
| 危害码 (欧洲) | Xn |
|---|
|
~94%
15763-11-8 |
| 文献:RELIABLE BIOPHARMACEUTICAL CORPORATION; WOOLDRIDGE, Luzviminda, T.; MA, Chun; NADJI, Sourena Patent: WO2012/149196 A1, 2012 ; Location in patent: Page/Page column 17 ; |
|
~82%
15763-11-8 |
| 文献:CV THERAPEUTICS, INC. Patent: WO2008/143667 A1, 2008 ; Location in patent: Page/Page column 20-21 ; WO 2008/143667 A1 |
|
~83%
15763-11-8 |
| 文献:Van Tilburg, Erica W.; Von Frijtag Drabbe Kuenzel, Jacobien; De Groote, Miriam; IJzerman, Ad P. Journal of Medicinal Chemistry, 2002 , vol. 45, # 2 p. 420 - 429 |
|
~88%
15763-11-8 |
| 文献:Niiya; Olsson; Thompson; Silvia; Ueeda Journal of Medicinal Chemistry, 1992 , vol. 35, # 24 p. 4557 - 4561 |
|
~%
15763-11-8 |
| 文献:Schaeffer; Thomas Journal of the American Chemical Society, 1958 , vol. 80, p. 3738,3741 |
|
~%
15763-11-8 |
| 文献:El-Tayeb, Ali; Gollos, Sabrina Bioorganic and Medicinal Chemistry, 2013 , vol. 21, # 2 p. 436 - 447 |
|
~%
15763-11-8 |
| 文献:El-Tayeb, Ali; Gollos, Sabrina Bioorganic and Medicinal Chemistry, 2013 , vol. 21, # 2 p. 436 - 447 |
|
~%
15763-11-8 |
| 文献:El-Tayeb, Ali; Gollos, Sabrina Bioorganic and Medicinal Chemistry, 2013 , vol. 21, # 2 p. 436 - 447 |
|
~%
15763-11-8 |
| 文献:El-Tayeb, Ali; Gollos, Sabrina Bioorganic and Medicinal Chemistry, 2013 , vol. 21, # 2 p. 436 - 447 |
| 上游产品 9 | |
|---|---|
| 下游产品 2 | |